Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial - Scorecard - MDSpire

Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial

  • By

  • Elena Murr

  • Sabine Grill

  • Marion Kiechle

  • Anne Kraemer

  • Bernadine Madl

  • Simon Glowka

  • Bernhard Haller

  • Caterina Fiorentini

  • Emmanuel Adjej

  • Mark J Haykowsky

  • Martin Halle

  • Simon Wernhart

  • June 5, 2026

  • 0 min

Share

Clinical Scorecard: Exercise Intervention in Localized Breast Cancer During Neoadjuvant Anthracycline Chemotherapy with Immune Checkpoint Inhibition: A Protocol for a Prospective Randomized Controlled Trial

At a Glance

CategoryDetail
Condition
Key MechanismsAnthracycline chemotherapy and immune checkpoint inhibition causing cardiotoxicity, specifically through reduced left ventricular ejection fraction and decreased VO2peak.
Target Population
Care Setting

Key Highlights

  • exercise_training

Guideline-Based Recommendations

Diagnosis

    Management

    • Supervised exercise training during neoadjuvant immunochemotherapy, including aerobic, resistance, and balance training.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Exercise training may mitigate treatment-related reductions in VO2peak by improving cardiac function and physical endurance.

        Clinical Best Practices

        • evidence

        Related Resources & Content

        Original Source(s)

        Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial

        • by Elena Murr, Sabine Grill, Marion Kiechle, Anne Kraemer, Bernadine Madl, Simon Glowka, Bernhard Haller, Caterina Fiorentini, Emmanuel Adjej, Mark J Haykowsky, Martin Halle, Simon Wernhart

        • June 5, 2026

        Related Content

        What RevMed’s pancreatic cancer drug meant for one patient

        A case report of splenic malignancy originating from the liver

        Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial